LSA
AXDX

L & S Advisors’s Accelerate Diagnostics AXDX Stock Holding History

L & S Advisors’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,339
Closed -$301K – 312
2017
Q3 		$301K Sell
1,339
-664
-33% -$163K 0.05% 220
2017
Q2 		$548K Buy
+2,003
New +$543K 0.1% 163

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.89B AUM 151.53% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

L & S Advisors's AXDX Position: Q4 2017 in Review

L & S Advisors sold out of Accelerate Diagnostics (AXDX) in Q4 2017, closing a stake of 1,339 shares — an estimated $301K sold.

L & S Advisors first reported a position in AXDX in Q2 2017 and held it in 2 quarters. The position peaked at $548K in Q2 2017. 118 funds tracked by Wall St. Rank hold AXDX as of Q4 2017.

  • L & S Advisors reported no remaining Accelerate Diagnostics position as of Q4 2017 after selling out during the quarter.
  • L & S Advisors sold 1,339 Accelerate Diagnostics shares in Q4 2017, an estimated $301K.
  • L & S Advisors first reported a position in Accelerate Diagnostics in Q2 2017 and held it in 2 quarters.
  • L & S Advisors's Accelerate Diagnostics position peaked at $548K in Q2 2017.
  • 118 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2017.

Based on L & S Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.